bispecific_2

Bispecific antibody-drug conjugates (BsADCs) are a new class of therapeutic drugs being developed to fight cancer. They combine the dual targeting ability of bispecific antibodies with the cell-killing power of cytotoxic drugs. BsADCs are designed to deliver cytotoxic drugs directly to cancer cells, while minimizing damage to healthy cells. While they are still in development, several exciting advances have occurred recently.

From hybridomas to recombinant platforms, antibody production has evolved. Biointron reveals ten insights into methods that ensure reliable supply and scientific progress.

Bispecific antibodies are transforming medicine. Biointron highlights their design, therapeutic applications, and development pathways for next-generation therapies.

Image credit: DOI: 10.3390/cancers16040800 In recent decades, the landscape of therapeutic antibodies has undergone a rapid evolution, catalyzing breakthroughs in modern medicine. These antibodies, characterized by their precise targeting and minimal side effects

Bispecific antibodies target two antigens at once. Biointron explores their formats, advantages, and therapeutic potential across cancer, immunology, and emerging indications.

Antibody combination therapies involve the use of two or more antibodies together as a treatment strategy to enhance the therapeutic effect against diseases, such as cancer or infectious diseases. This approach aims to target different epitopes or antigens simultaneously, increasing the efficacy of the treatment by overcoming resistance mechanisms, reducing the likelihood of disease escape, and providing a broader range of action.

Biointron delivers advanced bispecific antibody production with over 260 proven formats, offering rapid expression, scalable solutions, and trusted CRO expertise for therapeutic development.

Antibody engineering drives therapeutic innovation. Biointron advances bispecific design, Fc optimization, and humanization to enhance potency, reduce risks, and accelerate development.

Explore next‑generation antibody formats—bispecifics, trispecifics, and modular designs—that unlock new mechanisms, sharpen targeting, and raise the bar for developability.